A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Study to Evaluate the Efficacy and Safety of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)
Latest Information Update: 18 Mar 2025
At a glance
- Drugs Seralutinib (Primary)
- Indications Pulmonary arterial hypertension
- Focus Proof of concept; Therapeutic Use
- Acronyms TORREY
- Sponsors Gossamer Bio
- 13 Mar 2025 According to a Gossamer Bio media release, data from this study was presented at the Pulmonary Vascular Research Institute (PVRI) 2025 Annual Congress that took place January 29th through February 1st in Rio de Janeiro, Brazil.
- 22 May 2024 Results measuring Cardiac effort (CE), in a sub-study of this trial, presented at the 120th International Conference of the American Thoracic Society
- 22 May 2024 Results of exploratory analysis characterizing the impact of seralutinib on biomarkers and their correlation with hemodynamic response, presented at the 120th International Conference of the American Thoracic Society